$TDOC
Teladoc Health, Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022015977 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $637.7M $611.4M $521.7M
YoY Change 15.06% 17.2% 80.62%
Cost Of Revenue $188.9M $185.6M $169.0M
YoY Change 7.94% 9.81% 61.41%
Gross Profit $448.8M $425.8M $352.6M
YoY Change 18.35% 20.75% 91.55%
Gross Profit Margin 70.38% 69.64% 67.6%
Selling, General & Admin $324.2M $346.1M $165.6M
YoY Change 11.45% 108.97% 99.0%
% of Gross Profit 72.24% 81.28% 46.97%
Research & Development $77.58M $87.82M $80.25M
YoY Change 6.46% 9.43% 167.88%
% of Gross Profit 17.28% 20.62% 22.76%
Depreciation & Amortization $76.39M $62.71M $51.91M
YoY Change 45.97% 20.81% 237.72%
% of Gross Profit 17.02% 14.73% 14.72%
Operating Expenses $477.5M $495.9M $245.9M
YoY Change 14.76% 101.7% 117.23%
Operating Profit -$28.70M -$70.14M -$60.58M
YoY Change -22.16% 15.78% 207.1%
Interest Expense $1.893M -$1.346M -$18.90M
YoY Change -110.03% -92.88% 9.85%
% of Operating Profit
Other Income/Expense, Net $1.748M -$1.571M -$376.0K
YoY Change -531.6% 317.82% 49.21%
Pretax Income -$3.812B -$74.65M -$80.70M
YoY Change 6177.23% -7.5% 111.39%
Income Tax -$1.841M -$1.171M $3.600M
% Of Pretax Income
Net Earnings -$3.810B -$73.48M -$84.34M
YoY Change 34584.31% -12.88% 135.04%
Net Earnings / Revenue -597.46% -12.02% -16.17%
Basic Earnings Per Share -$0.45 -$0.53
Diluted Earnings Per Share -$23.49 -$454.3K -$529.0K
COMMON SHARES
Basic Shares Outstanding 161.9M 161.7M 159.2M
Diluted Shares Outstanding 161.7M 159.4M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $918.2M $899.6M $826.4M
YoY Change 2.48% 8.87% -30.58%
Cash & Equivalents $918.2M $899.6M $823.8M
Short-Term Investments $0.00 $0.00 $2.538M
Other Short-Term Assets $12.10M $126.9M $95.94M
YoY Change 113.85% 32.28% 336.1%
Inventory $56.34M $59.34M $56.94M
Prepaid Expenses $63.16M $59.14M
Receivables $210.6M $201.7M $178.1M
Other Receivables $25.09M $0.00 $0.00
Total Short-Term Assets $1.315B $1.288B $1.157B
YoY Change 7.34% 11.26% -11.66%
LONG-TERM ASSETS
Property, Plant & Equipment $29.64M $72.46M $27.03M
YoY Change 8.84% 168.09% 32.72%
Goodwill $1.073B $4.846B $14.47B
YoY Change -92.6% -66.51% 755.55%
Intangibles $1.837B $1.854B $1.932B
YoY Change -3.85% -4.02% 399.78%
Long-Term Investments
YoY Change
Other Assets $48.54M $43.66M $17.89M
YoY Change 134.46% 144.02% 151.37%
Total Long-Term Assets $3.030B $6.816B $16.50B
YoY Change -81.65% -58.68% 671.04%
TOTAL ASSETS
Total Short-Term Assets $1.315B $1.288B $1.157B
Total Long-Term Assets $3.030B $6.816B $16.50B
Total Assets $4.345B $8.104B $17.65B
YoY Change -75.5% -54.09% 411.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.69M $70.78M $34.66M
YoY Change 0.92% 104.25% 61.88%
Accrued Expenses $193.4M $240.3M $150.9M
YoY Change 19.4% 59.23% 37.21%
Deferred Revenue $101.8M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $11.38M $10.09M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $399.8M $411.4M $302.1M
YoY Change 20.77% 36.18% 50.43%
LONG-TERM LIABILITIES
Long-Term Debt $1.543B $1.542B $1.221B
YoY Change 24.97% 26.32% 26.78%
Other Long-Term Liabilities $1.618M $45.86M $1.328M
YoY Change 8.45% 3353.16% 28.56%
Total Long-Term Liabilities $1.618M $1.588B $1.328M
YoY Change 8.45% 119490.44% 28.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $399.8M $411.4M $302.1M
Total Long-Term Liabilities $1.618M $1.588B $1.328M
Total Liabilities $401.4M $2.051B $303.4M
YoY Change 20.72% 576.03% 50.32%
SHAREHOLDERS EQUITY
Retained Earnings -$15.01B -$11.20B -$1.410B
YoY Change 955.84% 693.94% 135.59%
Common Stock $17.36B $17.30B $17.40B
YoY Change -0.66% -0.57% 513.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.308B $6.053B $15.99B
YoY Change
Total Liabilities & Shareholders Equity $4.345B $8.104B $17.65B
YoY Change -75.5% -54.09% 411.76%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.810B -$73.48M -$84.34M
YoY Change 34584.31% -12.88% 135.04%
Depreciation, Depletion And Amortization $76.39M $62.71M $51.91M
YoY Change 45.97% 20.81% 237.72%
Cash From Operating Activities $65.55M $63.02M $76.59M
YoY Change -21.22% -17.72% 137.86%
INVESTING ACTIVITIES
Capital Expenditures $53.89M -$43.21M -$15.10M
YoY Change -335.12% 186.13% 62.37%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.757M -$19.61M
YoY Change -100.0% -108.96% -86.58%
Cash From Investing Activities -$53.89M -$41.45M -$34.71M
YoY Change 168.45% 19.42% -77.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.381M 634.0K 784.0K
YoY Change -33.87% -19.13% 86.67%
NET CHANGE
Cash From Operating Activities 65.55M 63.02M 76.59M
Cash From Investing Activities -53.89M -41.45M -34.71M
Cash From Financing Activities 4.381M 634.0K 784.0K
Net Change In Cash 16.04M 22.21M 42.67M
YoY Change -77.01% -47.95% -134.73%
FREE CASH FLOW
Cash From Operating Activities $65.55M $63.02M $76.59M
Capital Expenditures $53.89M -$43.21M -$15.10M
Free Cash Flow $11.66M $106.2M $91.69M
YoY Change -89.02% 15.85% 120.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity File Number
EntityFileNumber
001-37477
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161927087
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
899631000
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161727962
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159435165
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161217033
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
155926680
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20220930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
162195790
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
160469325
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-61.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.68
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20220930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001477449
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
893480000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2661000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2537000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
15311000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12384000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
201701000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
168956000
CY2022Q3 us-gaap Inventory Net
InventoryNet
59344000
CY2021Q4 us-gaap Inventory Net
InventoryNet
73079000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
126912000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
87387000
us-gaap Costs And Expenses
CostsAndExpenses
1702674000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
1287588000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1225439000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-38000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27270000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27234000
CY2022Q3 us-gaap Goodwill
Goodwill
4846001000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1854263000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1910278000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45187000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46780000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43656000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20703000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
45267000
CY2022Q3 us-gaap Assets
Assets
8103965000
CY2021Q4 us-gaap Assets
Assets
17734608000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
70783000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19407000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
47257000
CY2022Q3 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
177111000
CY2021Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
102933000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
63211000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
91941000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
90210000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
75569000
CY2022Q3 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
10086000
CY2021Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13313000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
411401000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
331013000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1632000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1492000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41080000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
39177000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41773000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3146000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3834000
CY2022Q3 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
7855000
CY2021Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9291000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
51742000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
75777000
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1534448000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1225671000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162195790
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
160469325
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
162000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
160000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17299981000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17473336000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11198216000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1421454000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-49266000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6285000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34566000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6052661000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8103965000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17734608000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
611402000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521658000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1769131000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1478472000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
185619000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-13709000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
169041000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
555114000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
475273000
CY2022Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
178920000
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
111078000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
477094000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
303738000
CY2022Q3 us-gaap Selling Expense
SellingExpense
54634000
CY2021Q3 us-gaap Selling Expense
SellingExpense
62602000
us-gaap Selling Expense
SellingExpense
170893000
us-gaap Selling Expense
SellingExpense
191251000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87815000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80250000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
256053000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
239017000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
112542000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103016000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
328333000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
319404000
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1594000
CY2021Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4340000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
8993000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
22084000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
62008000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
51907000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
180312000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
151907000
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
683132000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
582234000
us-gaap Costs And Expenses
CostsAndExpenses
11606792000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
635-2002
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TDOC
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-71730000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60576000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9837661000
us-gaap Operating Income Loss
OperatingIncomeLoss
-224202000
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-850000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-43728000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1571000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-376000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2607000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5493000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1346000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18895000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-11163000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-61493000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74647000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-80697000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9851431000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-323930000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1171000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3643000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1971000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93878000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73476000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-84340000
us-gaap Net Income Loss
NetIncomeLoss
-9849460000
us-gaap Net Income Loss
NetIncomeLoss
-417808000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19402000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13423000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-42981000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19650000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92878000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97763000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9892441000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-437458000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-61.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.68
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161727962
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159435165
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161217033
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
155926680
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6084650000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
666000
CY2022Q3 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60223000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19402000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73476000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6052661000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5646000
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4225000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180502000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42981000
us-gaap Net Income Loss
NetIncomeLoss
-9849460000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6052661000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
16001070000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5175000
CY2021Q3 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
74311000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13423000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-84340000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15987582000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22956000
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10539000
tdoc Recovered Excess Common Stock Issued For Acquisition Equity Impact
RecoveredExcessCommonStockIssuedForAcquisitionEquityImpact
40329000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
250027000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19650000
us-gaap Net Income Loss
NetIncomeLoss
-417808000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15987582000
us-gaap Net Income Loss
NetIncomeLoss
-9849460000
us-gaap Net Income Loss
NetIncomeLoss
-417808000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180312000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
151907000
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
2185000
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
2500000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
9266000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8185000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8867000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11353000
us-gaap Share Based Compensation
ShareBasedCompensation
167098000
us-gaap Share Based Compensation
ShareBasedCompensation
240971000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-5942000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
91414000
tdoc Accretion Of Interest
AccretionOfInterest
2496000
tdoc Accretion Of Interest
AccretionOfInterest
46843000
tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
0
tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
-40631000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
5901000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3677000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
22854000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3432000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24067000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11115000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
70046000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
15880000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-32028000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-17352000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12311000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20002000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-8111000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-8202000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2548000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1502000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
123743000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
110782000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10285000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5611000
us-gaap Payments For Software
PaymentsForSoftware
108588000
us-gaap Payments For Software
PaymentsForSoftware
35402000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2507000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
10901000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
75944000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2514000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3150000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-113852000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52906000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5646000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22956000
tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
0
tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
139000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
6807000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
10677000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
11470000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
12053000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3386000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
13996000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
594000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
3109000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2847000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4224000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2116000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34322000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12007000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
92198000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5856000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1694000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
893480000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
733324000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
899631000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
823828000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
901000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3114000
us-gaap Interest Paid
InterestPaid
8688000
us-gaap Interest Paid
InterestPaid
10380000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T</b><b style="font-weight:bold;">ELADOC HEALTH, INC. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care, forging a new healthcare experience with better convenience, outcomes, and value. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of chronic healthcare for individuals around the world. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.</p>
tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
3
tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
12
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the condensed consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant estimates and assumptions by management affect areas including the carrying value and useful life of long-lived assets (including intangible assets), the carrying value of goodwill, the capitalization and amortization of software development costs, deferred device and contract costs, sales and bad debt allowances, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">accounting for income taxes, contingences, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the 2021 Form 10-K.</p>
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
611402000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
521658000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1769131000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1478472000
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
93400000
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
76900000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14000000.0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21800000
CY2022Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
59500000
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
47200000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
68200000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
48500000
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
64500000
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
23800000
CY2022Q3 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
30762000
CY2021Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
22304000
CY2022Q3 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
9488000
CY2021Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
6249000
CY2022Q3 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
40250000
CY2021Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28553000
CY2021Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28553000
tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
41109000
tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
-29412000
CY2022Q3 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
40250000
CY2022Q3 tdoc Inventory Raw Materials And Purchased Parts Gross
InventoryRawMaterialsAndPurchasedPartsGross
27565000
CY2021Q4 tdoc Inventory Raw Materials And Purchased Parts Gross
InventoryRawMaterialsAndPurchasedPartsGross
28540000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1187000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
597000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
36803000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
49146000
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6211000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
5204000
CY2022Q3 us-gaap Inventory Net
InventoryNet
59344000
CY2021Q4 us-gaap Inventory Net
InventoryNet
73079000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7124000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
59141000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
38255000
CY2022Q3 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
30762000
CY2021Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
22304000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
24468000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
21168000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
12541000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5660000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
126912000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
87387000
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2370592000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
516329000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1854263000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2261768000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
351490000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1910278000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58200000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
171500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
145300000
CY2022Q3 tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategy
5800000
CY2022Q3 tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy Per Share
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategyPerShare
0.04
tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategy
17400000
tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy Per Share
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategyPerShare
0.11
CY2022Q3 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
21800000
CY2021Q4 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
2600000
CY2022Q3 tdoc Cloud Computing Expense
CloudComputingExpense
600000
tdoc Cloud Computing Expense
CloudComputingExpense
1100000
tdoc Cloud Computing Expense
CloudComputingExpense
100000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
64269000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0
CY2021 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-122306000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-28173000
CY2021 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-19044000
CY2022Q3 us-gaap Goodwill
Goodwill
4846001000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2022Q1 tdoc Goodwill Impairment Loss Per Share
GoodwillImpairmentLossPerShare
41.11
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3000000000.0
CY2022Q2 tdoc Goodwill Impairment Loss Per Share
GoodwillImpairmentLossPerShare
18.78
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9600000000
tdoc Goodwill Impairment Loss Per Share
GoodwillImpairmentLossPerShare
59.73
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
13424000
CY2022Q3 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
17243000
CY2021Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
19010000
CY2022Q3 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
4896000
CY2021Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
3034000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
5810000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1480000
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4511000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3098000
CY2022Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
8568000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3884000
CY2022Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
39075000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2958000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12864000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12687000
CY2022Q3 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
11454000
CY2021Q4 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
9965000
CY2022Q3 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
5925000
CY2021Q4 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
6263000
CY2022Q3 tdoc Other Current Liabilities Accrued Rebates
OtherCurrentLiabilitiesAccruedRebates
12581000
CY2021Q4 tdoc Other Current Liabilities Accrued Rebates
OtherCurrentLiabilitiesAccruedRebates
4619000
CY2022Q3 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
7582000
CY2021Q4 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
1858000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
33178000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26953000
CY2022Q3 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
177111000
CY2021Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
102933000
tdoc Fair Value Assets And Liabilities Transfers Between Fair Value Measurement Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenFairValueMeasurementLevelsAmount
0
CY2021 tdoc Fair Value Assets And Liabilities Transfers Between Fair Value Measurement Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenFairValueMeasurementLevelsAmount
0
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q3 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
17941000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
15095263
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3426978
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4339000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
15979000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10856000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8295000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7224000
CY2022Q3 tdoc Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
17695000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
64388000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10444000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
53944000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12864000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41080000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
3700000
CY2022Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
3700000
CY2022Q3 us-gaap Convertible Debt
ConvertibleDebt
1534448000
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
1225671000
CY2022Q3 tdoc Advances From Financing Companies Customer Payments Due Current
AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent
3375000
CY2022Q3 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
9708000
CY2022Q3 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
4290000
CY2022Q3 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
568000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.88
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M25D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
242569000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1407809
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.33
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
552400
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
23208000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
69761
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
57.38
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4212626
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.81
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23805000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4212626
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.81
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
23805000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2770160
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
22.06
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
23805000
CY2022Q3 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
300000
CY2021Q3 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
3000000.0
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
24900000
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
5800000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55662000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
71701000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
167098000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
240971000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000000.0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93900000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000000.0

Files In Submission

Name View Source Status
0001558370-22-015977-index-headers.html Edgar Link pending
0001558370-22-015977-index.html Edgar Link pending
0001558370-22-015977.txt Edgar Link pending
0001558370-22-015977-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20220930.xsd Edgar Link pending
tdoc-20220930x10q.htm Edgar Link pending
tdoc-20220930xex10d1.htm Edgar Link pending
tdoc-20220930xex31d1.htm Edgar Link pending
tdoc-20220930xex31d2.htm Edgar Link pending
tdoc-20220930xex32d1.htm Edgar Link pending
tdoc-20220930xex32d2.htm Edgar Link pending
tdoc-20220930_cal.xml Edgar Link unprocessable
tdoc-20220930_def.xml Edgar Link unprocessable
tdoc-20220930_pre.xml Edgar Link unprocessable
tdoc-20220930_lab.xml Edgar Link unprocessable
tdoc-20220930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable